NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$74.95 -1.70 (-2.22 %)
(As of 10/23/2018 04:06 AM ET)
Previous Close$76.65
Today's Range$72.34 - $76.45
52-Week Range$72.34 - $153.99
Volume697,116 shs
Average Volume903,298 shs
Market Capitalization$7.72 billion
P/E Ratio-13.83
Dividend YieldN/A
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.02
Current Ratio13.22
Quick Ratio13.22


Trailing P/E Ratio-13.83
Forward P/E Ratio-10.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$89.91 million
Price / Sales83.92
Cash FlowN/A
Price / CashN/A
Book Value$17.96 per share
Price / Book4.17


EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-533.52%
Return on Equity-38.09%
Return on Assets-33.43%


Outstanding Shares100,670,000
Market Cap$7.72 billion

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating analysts' consensus estimates of ($1.74) by $0.11. The biopharmaceutical company earned $29.91 million during the quarter, compared to the consensus estimate of $16.96 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. Alnylam Pharmaceuticals's quarterly revenue was up 87.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.07) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

18 analysts have issued 12-month price objectives for Alnylam Pharmaceuticals' stock. Their forecasts range from $73.00 to $230.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $146.5882 in the next year. This suggests a possible upside of 95.6% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.

What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now.  However,  In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release." (10/8/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and a target price of $135. Alnylam is a platform company that develops medicines using their RNA interference technology. We believe that Alnylam is at a key turning point in their history. They are launching their first commercial product and we are bullish about the potential. They have many late stage programs that could bring 4 more drugs to market over the next 2 years including givosiran, lumasiran, inclisiran, and fitusiran ." (10/1/2018)
  • 3. Needham & Company LLC analysts commented, "Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY." (9/13/2018)
  • 4. BMO Capital Markets analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. Revance remains on track to report results from the long-term safety study (SAKURA 3) of RT-002 in glabellar lines in 4Q18. Following this, Revance is expected to file its BLA for RT-002 in glabellar lines in 1H19. We continue to see RT-002 as a differentiated long duration neurotoxin that has the potential to seriously challenge the current market order." (8/3/2018)
  • 5. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 55)
  • Mr. Barry E. Greene, Pres (Age 55)
  • Mr. Manmeet Singh Soni, Sr. VP & CFO (Age 40)
  • Dr. Yvonne Greenstreet, Exec. VP & COO (Age 55)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 55)

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.20%), Bank of Montreal Can (0.06%), Aperio Group LLC (0.02%), Xact Kapitalforvaltning AB (0.02%), Essex Investment Management Co. LLC (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Essex Investment Management Co. LLC, DNB Asset Management AS, Aperio Group LLC and Nisa Investment Advisors LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $74.95.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $7.72 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]

MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  825 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  1,193
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel